Phase II study of continuation maintenance by use of TS1 after induction chemotherapy of cisplatin and TS1 in patients with Stage IIIB / IV non-small cell lung cancer-Research of efficacy predictive biomarker - Phase II of cisplatin and TS1 followed by TS1

Department of Respiratory Medicine National Center for Global health and Medicine0 个研究点目标入组 14 人开始时间: 2013年1月31日最近更新: 2023年10月17日

试验速览

暂无简介。

•1)History of allergic reaction for agents of present treatment 2)Severe myelosupperssion, renal dysfunction or hepatic dysfunction 3)Patients received post-operation adjuvant therapy within 6 months. 4)Active concomitant malignancy except carcinoma in situ, intramucosal carcinoma or cancer with more than 5 year disease free 5)Significant comorbid disease such as paresis of intestine, ileus, interstitial pneumonia, lung fibrosis, uncontrolled diabetes mellitus, cardiac failure, renal failure, hepatic failure, active gastrointestinal ulcer, myocardial infarction and angina pectoris within 6 months, other uncontrolled disease 6)Diarrhea more than and equal to grade 2 7)Active infection more than and equal to grade 2 8)Massive pleural effusion, peritoneal effusion or cardiac effusion required for tube drainage 9)Symptomatic brain metastasis but eligible for controlled brain metastases 10)Patients required for continuing steroid therapy 11)Pregnant status or lactation 12)Uncontrolled psychiatric disease 13)Other ineligible status judged by medical oncologist.

发起方

Department of Respiratory Medicine National Center for Global health and Medicine